Dermira Profile

USD 1.16  12.75%

Sale by David Cohen of 600 shares of Dermira

Dermira Inc insider trading alert for sale of common stock by David Cohen, the corporate stakeholder, on March 2, 2018. This event was filed by Dermira Inc with SEC on 2018-03-02. Statement of changes in beneficial ownership - SEC Form 4 [view details]   

Dermira Summary

Dermira Inc (DERM) is traded on NASDAQ in USA. It is located in CALIFORNIA, U.S.A and employs 162 people. Dermira is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Small-Cap' category with current market capitalization of 429.09 M. Dermira Inc conducts business under Healthcare sector and is part of Biotechnology industry. This company has 41.82 M outstanding shares of which 5.09 M shares are currently shorted by private and institutional investors with about 12.21 trading days to cover. Dermira currently holds about 550.99 M in cash with (103.96 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 13.18 which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Dermira Probability Of Bankruptcy

Ownership Allocation (%)

Top Holders

Selected Dermira Inc Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Key Fundamentals

Dermira Against Markets

Risk Adjusted
Performance Score (0 to 100)
Chance of
Financial Distress (0 to 100%)
< 44% 
Equity ratings for Dermira Inc are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
Dermira, Inc., a biopharmaceutical company, identifies, develops, and commercializes therapies to treat dermatologic diseases. Dermira, Inc. was founded in 2010 and is headquartered in Menlo Park, California. Dermira operates under Biotechnology classification in USA and traded on NASDAQ exchange. It employs 162 people. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
NameDermira Inc
Chairman of the BoardWilliam YoungView All
Analyst Consensus
Piotroski F Score
Macroaxis Advice
InstrumentUSA Stock View All
RegionNorth America
Business Address275 Middlefield Road
CIK Number01557883.0
Contact Number650 421 7200
CurrencyUSD - US Dollar


Dermira Analyst Recommendations
Target PriceAdvice# of Analysts
44.33Strong Buy3Odds
Dermira Inc current and past analyst recommendations published by number of research institutions as well as average analyst consensus
Dermira Analyst Advice  


Explore Investment Opportunities
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked.
Explore Investing Ideas  


Dermira Earnings Estimates
Dermira Inc normalized analysts earnings estimates for actual as well as projected forward EPS values taken as an average expert opinion over time
Earnings Estimate  


Dermira Corporate Directors
Jake Nunn Independent Director, CFA
Frederick Craves Independent Director
Matthew Fust Independent Director, MBA